Accession Number : ADA612558


Title :   Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic


Descriptive Note : Annual rept. 15 Aug 2013-14 Aug 2014


Corporate Author : COLORADO UNIV AURORA CO


Personal Author(s) : Richer, Jennifer K


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a612558.pdf


Report Date : Sep 2014


Pagination or Media Count : 104


Abstract : In breast cancers, the androgen receptor (AR) is more widely expressed than estrogen receptor alpha (ER) or the progesterone receptor (PR) (1), which are used as therapeutic targets and biomarkers, suggesting a potential role for AR in BC. To explore the function of AR in models of the three main subtypes of breast cancer (ER positive, ER negative and Her2+), we are using a new-generation AR inhibitor, enzalutamide, which impairs nuclear localization of AR. This is a very different mode of action than previous generation anti-androgens such as bicalutamide (Casodex), which is a competitive inhibitor of endogenous androgens that allows ligand-mediated nuclear localization of AR. Enzalutamide has shown success in the clinic in patients with late stage prostate cancer. The research in this proposal seeks to determine whether inhibition of AR with enzalutamide will be effective in breast cancer and utilize preclinical models to determine if and how it should be combined with currently used standard of care treatments in the three main types of breast cancer, with the primary objectives of the research being to guide the design of future clinical trials with enzalutamide.


Descriptors :   *ANDROGENS , *BREAST CANCER , *DRUGS , *ESTROGENS , *RECEPTOR SITES(PHYSIOLOGY) , ENDOCRINE GLANDS , INHIBITION , PROGESTERONE , RESISTANCE(BIOLOGY)


Subject Categories : Biochemistry
      Anatomy and Physiology
      Medicine and Medical Research
      Pharmacology


Distribution Statement : APPROVED FOR PUBLIC RELEASE